Member area login
You don't have or don't remember the password!
Click Here
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282


ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da G.C. Guidi

miR-199a and miR-125b expression levels in serum of women affected by epithelial ovarian cancer
<p>Recent studies show that microRNA (miRNAs) are involved in cancer by regulating cell proliferation, apoptosis and angiogenesis. Accordingly, their deregulation could contribute to cancer development and progression. It has been demonstrated that in ovarian tissue the over-expression of miR-199a and miR-125b inhibits tumor angiogenesis, a fundamental process for cancer development and growth. Aims of our study were to investigate the expression levels of miR-199a and miR-125b in serum of patients with ovarian cancer (OC) and to evaluate the correlation between miRNAs expression and traditional biomarkers [CA125 and human epididymis protein 4 (HE4)]. 32 patients with epithelial OC (54&plusmn;14 years old) and 31 healthy controls (55&plusmn;17 years old) were enrolled. Serum samples were collected prior to definitive surgical treatment and RNA extraction was performed by using the miRNeasy Serum/Plasma kit (Qiagen GmbH). miR-199a and miR-125b expression was determined by quantitative real timepolymerase chain reaction (TaqMan MicroRNA Assay, Applied Biosystems). The expression levels of miRNAs were normalized to miR-16 and calculated utilizing the 2-&Delta;Ct method. Serum levels of miR-199a and miR-125b were significantly higher in OC patients compared to controls (P=0.007 and P=0.002, respectively). A marginally statistically significant correlation was found between miR-199a and miR-125b expression levels (r=0.38, P=0.03). The ROC curve analysis of the diagnostic performance between healthy controls and OC patients revealed that HE4 had a significantly higher area under the curve (AUC=0.90) when compared to CA125 (AUC=0.85), miR-199a (AUC=0.70) and miR-125b (AUC=0.67). Anyway, the determination of circulating miRNAs may be relevant, since their expression is known to be aberrant in cancer, having potential ability to monitor tumor dynamics.</p>
Biochimica Clinica ; 40(4) 328-333
Contributi scientifici - Scientific Papers
Dabigatran e analisi di laboratorio
Dabigatran and laboratory tests
R. Facchinetti  |  B. Capizzi  |  B. Caruso  |  M. Negri  |  R. Suppi  |  G. Molon  |  G.C. Guidi  | 
<p>New oral anticoagulants (i.e., dabigatran, rivaroxaban, apixaban) are now&nbsp;available. In using these drugs, routine monitoring of laboratory coagulation tests is not recommended. In some&nbsp;clinical conditions, however, a laboratory evaluation of hemostatic balance may be useful. Tests suggested for&nbsp;laboratory monitoring of dabigatran treatment are thrombin time on undiluted (TT) or diluted (dTT) plasma and ecarin&nbsp;clotting time. On 30 patients taking dabigatran for non valvular atrial fibrillation, we assayed dabigatran levels by dTT,&nbsp;also performing prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and TT. In patients&nbsp;taking dabigatran etexilate 110 mg bis in die and 150 mg bis in die, dTT mean results (10<sup>th</sup>-90<sup>th</sup> percentile) were 97&nbsp;(32-152) and 94 (33-189) &mu;g/L, respectively. In dTT range from 13 to 60 &mu;g/L and &gt;60 &mu;g/L, we obtained 27% and&nbsp;58% prolonged PT, 64% and 95% prolonged APTT, and 100% and 100% prolonged TT, respectively, showing that for&nbsp;dabigatran TT is a useful screening test.</p>
Biochimica Clinica ; 39(1) 041-047
Contributi scientifici - Scientific Papers
Determinazione dell’ormone anti-mulleriano per la valutazione della riserva ovarica in pazienti dopo trattamento chemioterapico
Utility of anti-mullerian hormone for the evaluation of fertility preservation in female patients after chemotherapy
<p>The new advances in the treatment have greatly increased the life expectancy of premenopausal women with&nbsp;hematological malignancies. The susceptibility of their ovarian reserve to chemotherapy is however highly variable. The&nbsp;anti-mullerian hormone (AMH) is one of the most sensitive markers of ovarian reserve and fertility preservation. In this study,&nbsp;antral follicle counts (AFC), serum AMH, follicle stimulating hormone (FSH) and inhibin B were assayed in female patients&nbsp;treated for lymphoma and hematological disease to characterize the evolution of fertility preservation. 63 consecutive&nbsp;women (48 with Hodgkin&#39;s lymphoma, 9 non-Hodgkin&#39;s lymphoma, 6 acute myeloid leukemia) were eligible for enrolment.&nbsp;All patients [median age, 31 years (range: 17-40)] were in complete remission with a median follow-up time of 9.0 years&nbsp;after therapy. 64 healthy controls were also evaluated [median age, 31 years (range: 20-42)]. Participants had a baseline&nbsp;blood drawing during the early follicular phase of the menstrual cycle. A significant difference in AFC (9.8 vs. 16.0,&nbsp;P=0.0001), AMH (2.02 &mu;g/L vs. 2.97 &mu;g/L, P=0.02), FSH (16.9 U/L vs. 8.1 U/L, P=0.03) and inhibin B (33.7 ng/L vs. 69.4&nbsp;ng/L, P &lt;0.005) was observed between patients and controls. The ROC curve analysis comparing AMH and FSH&nbsp;concentrations of patients (at the same AFC cut-off point of 8) revealed that AMH had a better area under the curve (0.904)&nbsp;than FSH (0.678) (P=0.0013). The ovarian reserve is reduced in female patients affected by hematological malignancies&nbsp;after chemotheraphy. AMH is the most reliable serum marker of fertility preservation in these subjects.</p>
Biochimica Clinica ; 38(5) 374-377
Contributi scientifici - Scientific Papers
Nuovi approcci diagnostici al ritardo mentale
New diagnostic approaches to mental retardation
<p>Genomic imbalances are considered the most frequent causes of mental retardation (MR). Although widespread screening with novel molecular karyotyping methods, such as multiplex ligation-dependent probe amplification (MLPA) and array-based comparative genomic hybridization (Array-CGH) might be desirable, effective clinical preselection is essential because of the technical complexities and cost of testing. This study focuses on a retrospective analysis of clinical features in patients with MR of unknown etiology,thereby assessing the sensitivity of a six item checklist in identifying rearranged subjects. The diagnostic powers of single techniques were also evaluated. We studied 164 subjects with MR who had completed the follow diagnostic process: karyotype and eventually fluorescence in situ hybridization (FISH) in case of suspected microdeletion syndrome, specific analysis in case of suspected X-linked or monogenic disease, MLPA for subtelomeric rearrangements in patients negative to previous tests, Array-CGH in patients negative to MLPA. A six items checklist based on relevant clinical signs was retrospectively applied. 5 patients were carrier of chromosomal abnormalities (3 detected by karyotype and 2 by FISH), 3 were affected by X-fragile syndrome, 6 had mutations, and 33 were carriers of genomic imbalances (9 detected by MLPA and 24 by Array-CGH), while 117 resulted negative to any tests. In patients with genomic imbalances and in subjects without rearrangements the median score of the checklist was 6 (range 3-9) and 4 (range 0-8), respectively (P &lt;0,0001). The ROC analysis for the diagnostic accuracy of our checklist showed an area under the curve of 0.74 (95% confidence interval: 0.65-0.83). Using a cut-off for the score of U3, 24% of patients could have been excluded without missing any genomic imbalances. This study supports the evidence that the application of a clinical checklist may improve the rate of pathological findings in patients with MR.</p>
Biochimica Clinica ; 36(3) 187-192
Contributi Scientifici - Scientific Papers
Determinazione della variabilità biologica dell'emoglobina A2
Determination of biological variation of hemoglobin A2.
R. Paleari  |  M. Montagnana  |  E. Danese  |  M. Tozzi  |  G.C. Guidi  |  A. Mosca  | 
<p><strong>Determination of biological variation of hemoglobin A2.</strong> We present an experimental report aimed to evaluate the biological variation of hemoglobin A2 (HbA2), a minor hemoglobin component in post-natal life, accounting for 2.5%-3.5% of the total hemoglobin in red cells, which is very relevant for the laboratory diagnosis of thalassemic syndromes. We took five blood specimens from 17 apparently healthy subjects (9 men and 8 women, ages 26-52 years) on the same day, every two weeks for two months. Samples were stored at -80 &#176;C until analysis and assayed in duplicate by Bio-Rad Variant II analyzer. Data were analyzed by the ANOVA. There were no differences in HbA2 values between men and women. HbA2 exhibited marked individuality: within- (CVI) and between-subject (CVG) biological variation were 0.7% and 7.7%, respectively. Desirable analytical goals derived from biological variation for imprecision (0.5 CVI), bias [0.25 (CVI2 + CVG2)1/2] and total error [1.65 (0.5 CVI) + 0.25 (CVI2 + CVG2)1/2]were 0.4%, 1.9%, and 3.1%, respectively. In conclusion, this is the first evidence that HbA2, as well as total hemoglobin, is under a strict homeostatic control. Our data also show that stringent analytical goals are needed for the clinical application of HbA2 measurements.</p>
Biochimica Clinica ; 35(6) 458-460
Valutazione del "risk of ovarian malignancy algorithm" (ROMA) nella stima del rischio di tumore epiteliale maligno dell'ovaio in donne con massa pelvica
The "risk of ovarian malignancy algorithm" for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass.
Biochimica Clinica ; 35(1) 30